These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27999054)

  • 21. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
    Semu M; Fenta TG; Medhin G; Assefa D
    BMC Infect Dis; 2017 Jan; 17(1):5. PubMed ID: 28049455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009-2014.
    Salindri AD; Sales RF; DiMiceli L; Schechter MC; Kempker RR; Magee MJ
    Ann Am Thorac Soc; 2018 Mar; 15(3):331-340. PubMed ID: 29131662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.
    Fox L; Kramer MR; Haim I; Priess R; Metvachuk A; Shitrit D
    Eur J Clin Microbiol Infect Dis; 2011 Jul; 30(7):863-7. PubMed ID: 21431989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana.
    Sibanda T; Tedla Z; Nyirenda S; Agizew T; Marape M; Miranda AG; Reuter H; Johnson JL; Samandari T
    Int J Tuberc Lung Dis; 2013 Feb; 17(2):178-85. PubMed ID: 23317952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
    Nyathi S; Dlodlo RA; Satyanarayana S; Takarinda KC; Tweya H; Hove S; Matambo R; Mandewo W; Nyathi K; Sibanda E; Harries AD
    PLoS One; 2019; 14(10):e0223076. PubMed ID: 31581271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study.
    Hermans SM; Grant AD; Chihota V; Lewis JJ; Vynnycky E; Churchyard GJ; Fielding KL
    BMC Med; 2016 Mar; 14():45. PubMed ID: 27004413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.
    Dhungana GP; Thekkur P; Chinnakali P; Bhatta U; Pandey B; Zhang WH
    BMJ Open; 2019 May; 9(5):e029058. PubMed ID: 31147370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam.
    Bakari M; Moshi A; Aris EA; Chale S; Josiah R; Magao P; Pallangyo N; Mugusi F; Sandström E; Biberfeld G; Mhalu F; Pallangyo K
    East Afr Med J; 2000 Sep; 77(9):494-7. PubMed ID: 12862141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania.
    Maokola WM; Ngowi BJ; Mahande MJ; Todd J; Robert M; Msuya SE
    PLoS One; 2021; 16(7):e0254082. PubMed ID: 34255776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.
    Assebe LF; Reda HL; Wubeneh AD; Lerebo WT; Lambert SM
    BMC Public Health; 2015 Apr; 15():346. PubMed ID: 25886730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis.
    Thai PVK; Ha DTM; Hanh NT; Day J; Dunstan S; Nhu NTQ; Kiet VS; Lan NH; Dung NH; Lan NTN; Thuong NT; Lan NN; Liễu PTT; Hồng NT; Điệp ĐC; Thanh NTK; Hội NV; Nghĩa NV; Đại TN; Minh HQ; Thơm NV; Farrar J; Caws M
    BMC Infect Dis; 2018 Mar; 18(1):112. PubMed ID: 29510687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
    Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
    J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
    Nyarubamba RF; Silumbwe A; Jacobs C; Maritim P; Mdoe P; Zulu JM
    BMC Infect Dis; 2022 Nov; 22(1):884. PubMed ID: 36434517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting.
    Padmapriyadarsini C; Sekar L; Reddy D; Chitra A; Poornagangadevi N; Selvaraj M; Bhavani PK; Mothi SN; Nandagopal K; Vennila S; Tamizhselvan M; Maheshmanisha J; Agarwal U; Rewari BB; Swaminathan S
    Indian J Med Res; 2020 Dec; 152(6):648-655. PubMed ID: 34145105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.
    Gezae KE; Abebe HT; Gebretsadik LG
    BMC Infect Dis; 2019 Feb; 19(1):107. PubMed ID: 30717705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017.
    Edwards BD; Edwards J; Cooper R; Kunimoto D; Somayaji R; Fisher D
    PLoS One; 2020; 15(3):e0229691. PubMed ID: 32155169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam.
    Cowger TL; Thai LH; Duong BD; Danyuttapolchai J; Kittimunkong S; Nhung NV; Nhan DT; Monkongdee P; Thoa CK; Khanh VT; Nateniyom S; Yen NTB; Ngoc DV; Thinh T; Whitehead S; Pevzner ES
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):512-521. PubMed ID: 29023251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study.
    Ayele HT; van Mourik MS; Bonten MJ
    BMC Infect Dis; 2015 Aug; 15():334. PubMed ID: 26269094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.
    van Halsema CL; Fielding KL; Chihota VN; Russell EC; Lewis JJ; Churchyard GJ; Grant AD
    AIDS; 2010 Apr; 24(7):1051-5. PubMed ID: 20299958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.